Because emerging evidence suggests that fetuin-A may serve as a therapeutic target for metabolic disorders, including insulin resistance and type 2 diabetes, discovery of a liver-specific PPARγ agonist will provide the potential for an entirely new approach to treating metabolic disorders through fetuin-A regulation. Here, PPARG is linked to metabolic disease.